

# Combination immunotherapy targets cancer resistance

November 22 2017, by Ziba Kashef

---




Image shows infiltration of transplanted human cancer cells (yellow/orange) by two myeloid cell subsets (red and green) in a mouse model treated with combination immunotherapy. Credit: Yale University

Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental

antibody that overcomes this problem by targeting a wider range of immune cells linked to tumor growth.

Existing cancer immunotherapies act on only a fraction of immune cells implicated in the disease. In this study, the research team developed an antibody, KWAR23, to block a different set of [immune cells](#) known as [myeloid cells](#). Many of these cells infiltrate tumors, triggering [tumor growth](#), inflammation, and resistance to treatment.

In both cell culture and in mouse models with human cell membrane proteins, the research team found that the antibody blocked a protein that would otherwise limit the tumor-killing ability of myeloid cells. In combination with an approved cancer immunotherapy drug, the antibody significantly limited tumor cell growth.

The finding demonstrates a promising combination therapeutic approach to more effectively fight tumors, the researchers said. It will also lead to further research to examine whether the antibody is also effective in reducing more advanced and metastatic cancers.

The study is published in *PNAS*.

**More information:** Nan Guo Ring et al. Anti-SIRP $\alpha$  antibody immunotherapy enhances neutrophil and macrophage antitumor activity, *Proceedings of the National Academy of Sciences* (2017). [DOI: 10.1073/pnas.1710877114](https://doi.org/10.1073/pnas.1710877114)

Provided by Yale University

Citation: Combination immunotherapy targets cancer resistance (2017, November 22) retrieved 19 April 2024 from

<https://medicalxpress.com/news/2017-11-combination-immunotherapy-cancer-resistance.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.